Global Liquid Biopsy market is expected to grow at a CAGR of ~ 28 % by 2022

Market research future published a cooked research report on global liquid biopsy market. The global liquid biopsy market is expected to grow at a CAGR of ~ 28% during the period of 2015 to 2022.

Global Liquid Biopsy Market Information, by Biomarker Types (Circulating Tumor Cells (Ctcs), Circulating Tumor Dna (Ctdna), Extracellular Vesicles (Evs) and Other Biomarker (Circulating Rna And Proteins), by Application (Cancer Therapeutic Application, Reproductive Health, Other Therapeutic Application), by Sample (Blood Sample, Urine Sample, Other) And End User (Hospitals and Laboratories, Academic And Research Centers, Other End Users) - Forecast to 2022

Market Highlights
Biopsy involves extracting a sample of tissue and testing it for the presence of diseases especially cancer. Traditional tissue biopsy is a painful technique and also has a high rate of false results. Moreover the technique is costly, time consuming and not applicable for extracting samples such as those close to vital organs such as heart. Liquid biopsy overcomes these problems of tissue biopsy by using biomarkers present in samples such as blood, urine etc. and thus is a comparatively non-invasive technique. Liquid biopsy also provides greater information about the sample which is real time. The real time data can be used for monitoring and thereby determining the treatment for diseases such as cancer. The greater sensitivity of tissue biopsy coupled with the development of sophisticated detectors with extremely low detection rates have enabled the early detection of diseases which is the holy grail of cancer.
Other market drivers for the liquid biopsy market are rising rates of cancer, growing investment in research and development, collaborations between companies and public organizations, rise in geriatric population, rising expenditure on health etc. The factors which are inhibiting the growth of the market includes the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. However, not all cancer patients benefit from early detection as some cancer types such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Major Players of Global liquid biopsy market:
The major participants of this market are: Guardant Health, Inc., Trovagene, Inc., RainDance Technologies, Inc., Agena Bioscience Inc. Inc., Admera Health, Biocept, Inc., Circulogene Theranostics, Inivata Ltd., SAGA Diagnostics AB, Exosome Diagnostics and others.

Sample Report Available at https://www.marketresearchfuture.com/sample_request/710 .
Key findings
• Circulating tumor cells (CTCs) segment dominates both in terms of market share as well as revenues, contributing approx. 55.48% of the revenue share of the liquid biopsy market.
• On the basis of the therapeutic application, the segment for Cancer will reflect the highest growth potential, with over 82.83% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth.
• The market for liquid biopsy is dominated by North America and Europe and this trend will continue. Asia-Pacific market is the fastest growing market and is expected to grow at a CAGR of 29.7% during forecasted period

Segments:
Global Liquid Biopsy market has been segmented on the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker. On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application. On the basis of sample; market is segmented into blood, urine and others. On the basis of end-users; market is segmented into hospitals and laboratories, academic and research centers and others.

Regional Analysis of Global Liquid Biopsy market:
Globally North America is the largest market for Global Liquid Biopsy market. Europe is the second-largest market for Global Liquid Biopsy market. However the developing regions market particularly Asia Pacific will be the fastest growing and will be the key to the future. North America accounted for the largest market share of 37.95% in 2016 accounting for a market value of 1,499.10 million in 2016. Asia pacific is the fastest growing market which is growing at a CAGR of 28.8%.

Browse complete report at https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710 .
Table of Content
1. Report Prologue
2. Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4. Market Segmentation
3. Research Methodology
4. Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Comparatively painless and non-invasive technique
4.2.2 Early real time high precision detection of diseases
4.2.3 Useful for designing effective treatment strategies based on the real time molecular assessment for the progression of the disease
4.2.4 Rise in cases of cancer and other diseases
4.2.5 Lifestyle changes and environmental factors
4.2.6 Other advantages over other techniques
4.2.7 The recent technological advancements has increased the appeal of liquid biopsy
4.2.8 Transferability of liquid biopsy
4.2.9 Rising investment in research and development and collaborations between companies and public organizations
4.2.10 Greater focus on venture capital
4.2.11 Demographical factors
4.3 Restraints
4.3.1 Prohibitive costs associated with liquid biopsy
4.3.2 Lower sensitivity for certain biomarkers
4.3.3 Not all cancers patients benefit from early detection
4.3.4 Liquid biopsy is not all non-invasive
4.3.5 Differential awareness and availability between developing and developed world
4.3.6 Issues in venture capital, startups and collaborations
4.4 Opportunities
4.4.1 Growing collaboration between companies has become the entrance gateway for new firms
4.4.2 Funding from public organizations is a good strategy to reduce development costs
4.4.3 Rise in research and development investment
4.4.4 Developing economies provide an unserved market for liquid biopsy
4.4.5 Growing trend of start-ups and venture investment in the field of liquid biopsy
4.5 Challenges
4.5.1 Information and interest gap between the investors and the developers
4.5.2 Lack of trained professionals in developing regions
4.5.3 Lack of standardization and transparency

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@Marketresearchfuture.Com

This release was published on openPR.